Anti-IgE for the Treatment of Chronic Urticaria. (PubMed, Immunotargets Ther) - Feb 26, 2021 - "Phase 2 b results of ligelizumab have not only demonstrated efficacy and safety but also superiority to omalizumab. Whereas further development of quilizumab was discontinued, other approaches, eg UB-221 or DARPins are under investigation. Anti-IgE treatment with omalizumab represents a landmark in the treatment of chronic urticaria, with and without angioedema, and there is light on the horizon suggesting success may come with various next-generation anti-IgE approaches."
Clinical • Journal • Review • Cardiovascular • Chronic Spontaneous Urticaria • Dermatology • Urticaria
|